

### **REMARKS**

Favorable reconsideration is respectfully requested in view of the foregoing amendments and following remarks.

The specification has been amended as suggested by the Examiner to capitalize the trademarks appearing on pages 12 and 13.

The title of the invention has been revised as suggested by the Examiner.

Claims 10, 11 and 14 have been cancelled without prejudice and replaced with new claims 16 and 17. The wording of the new claims have been drafted to overcome the grounds of rejection set forth by the Examiner under 35 USC 112, first and second paragraphs. Specifically, the "animal" recited in claim 10 has been limited to a human. The "biological sample" has been amended to that "being obtained from colon tissue or intestine tissue". The phrase "analyzing the expression" has been clarified to recite "analyzing the level of gene expression". The expression "gene of" has been clarified to read "gene encoding". New claim 16 recites an additional limitation "wherein an increased level of gene expression is an indicator of Crohn's disease". Lastly, new claim 16 recites a third step of "diagnosing Crohn's disease based upon a finding of an increased level of gene expression".

In view of the foregoing, it is believed that each ground of rejection set forth in the Official Action have been overcome.

Favorable reconsideration and allowance is respectfully solicited.

Respectfully submitted,

Katsushi TOKUNAGA et al.

By: Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
July 25, 2003